To read the full article sign up for free or sign in.

Bavarian Nordic bets on Adaptvac VLP technology for COVID-19 vaccine push

May 6, 2020

DUBLIN – Bavarian Nordic A/S, Europe’s largest independent vaccine developer, is placing a bet on virus-like particle (VLP) technology as a potentially useful contribution to the desperate global effort to push back against SARS-CoV-2.

BioWorld Deals and M&A Coronavirus Vaccine

Today's news in brief

BioWorld

BioWorld briefs for July 14, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 14, 2025.

Incurix describes new c-Myc inhibitors

BioWorld Science

Incurix Co. Ltd. has identified Myc proto-oncogene protein (c-Myc) inhibitors reported to be useful for the treatment of cancer.

3D rendering of a molecular glue mediating the interaction between two proteins

With surface mimicry, molecular glues shed hairpin need

BioWorld Science

Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...

AI-generated illustration of CAR T cells

Researchers arm CAR T cells to fight solid tumors

BioWorld

Aussie researchers have used CRISPR gene editing tools to “armor” chimeric antigen receptor (CAR) T cells to activate additional cancer-fighting proteins at the...